Mien-Chie Hung

This inventor holds 34 USPTO granted patents and 5 published patent applications and 5 EPO patents, primarily in Cancer Immunotherapy. Top assignees: The University of Texas System, Stcube, Inc., Kuo Kwang Biotech Corporation. Active years: 1997-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mien-Chie Hung. Retrieved from https://idiyas.com/inventor/mien-chie-hung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 (Patent Applications = 5)

% Patents Active = 70.6

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 3.3

ph-index = 8

Forward Citations = 173(Granted Patents)

Company Filing History:

33 out of 5,633

The University of Texas System

Kuo Kwang Biotech Corporation

Texas A&M University System

patents

where one patent can have more than one assignee

Years Active: 1997-2024

Loading Chart...

Areas of Expertise:

Glycosylated Antibodies

PD-1

PD-L1

Cancer Treatment

Tumor Suppressors

Personalized Medicine

Resistance Prediction

Therapeutic Targets

Molecule-Molecule Interactions

Liposomal Formulations

Arginine Methylation

Cancer Specific Promoters

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12059474 - Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins (2024-08-13),

2. 11981736 - Antibodies specific to glycosylated PD-1 and methods of use thereof (2024-05-14),

3. 11933786 - Antibodies specific to glycosylated PD-L1 and methods of use thereof (2024-03-19),

4. 11746152 - Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1 (2023-09-05),

5. 11660352 - Dual function antibodies specific to glycosylated PD-L1 and methods of use thereof (2023-05-30),

6. 11452775 - Detection of arginine methylation of EGFR for prediction of resistance to therapy (2022-09-27),

7. 10858432 - Antibodies specific to glycosylated PD-1 and methods of use thereof (2020-12-08),

8. 10836827 - Antibodies specific to glycosylated PD-L1 and methods of use thereof (2020-11-17),

9. 10537635 - Detection of arginine methylation of EGFR for prediction of resistance to therapy (2020-01-21),

10. 10451610 - Prediction of response to PARP inhibitors and combinational therapy targeting C-MET and PARP1 (2019-10-22),

11. 9655909 - Personalized medicine for the prediction of therapy targeting the hedgehog pathway (2017-05-23),

12. 8586316 - Methods for detecting molecule-molecule interactions with a single detection channel (2013-11-19),

13. 8304526 - Antitumor effect of mutant Bik (2012-11-06),

14. 7906628 - Targeting proteins to deliver therapeutic or diagnostic reagents (2011-03-15),

15. 7893033 - Targeting proteins to deliver therapeutic or diagnostic reagents (2011-02-22),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I am excited to present an article about the renowned inventor Mien-Chie Hung and his impactful contributions to the field of biomedicine.

Title:

Mien-Chie Hung: Pioneering Innovations in Biomedicine

Introduction:

Inventor Mien-Chie Hung, based in Houston, TX, is a visionary figure whose dedication to innovation and pursuit of scientific excellence continues to inspire the next generation of inventors and researchers in the realm of biomedicine.

Latest Patents:

With an impressive portfolio of 34 patents, Hung's latest inventions focus on groundbreaking methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins. These antibodies have shown potential in disrupting cancer therapeutics and blocking immunosuppression mechanisms.

Career Highlights:

Throughout his illustrious career, Mien-Chie Hung has been associated with esteemed institutions such as the University of Texas System and StCube, Inc. His expertise and passion for pioneering research have led to significant advancements in the understanding and treatment of various medical conditions.

Collaborations:

Hung has collaborated closely with accomplished researchers in the field, including Chia-Wei Li and Seung-Oe Lim. Together, they have worked on cutting-edge projects that have the potential to revolutionize the landscape of biomedicine and oncology.

Conclusion:

In conclusion, Mien-Chie Hung stands as a beacon of innovation in the field of biomedicine, with his groundbreaking research and relentless pursuit of scientific excellence setting a high standard for the next generation of inventors and researchers. His patents not only showcase his ingenuity but also pave the way for novel approaches in cancer therapeutics and immunosuppression treatments.

Profile summary based on public USPTO records.